Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 12, pp 4108–4116 | Cite as

Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival

  • Ariella M. Altman
  • Keith Wirth
  • Schelomo Marmor
  • Emil Lou
  • Katherine Chang
  • Jane Y. C. Hui
  • Todd M. Tuttle
  • Eric H. Jensen
  • Jason W. DenboEmail author
Hepatobiliary Tumors

Abstract

Background

Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for completion of adjuvant chemotherapy, factors associated with completion, and its impact on survival after surgical resection.

Methods

The Surveillance Epidemiology and End Results Medicare-linked data was used to identify patients who underwent upfront resection for pancreatic adenocarcinoma from 2004 to 2013. Billing codes were used to quantify receipt and completion of chemotherapy. Factors associated with completion of chemotherapy were identified using multivariable regression. Kaplan–Meier and Cox proportional-hazards modeling were used to examine survival.

Results

The inclusion criteria were met by 2440 patients. Of these patients, 65% received no adjuvant chemotherapy, 28% received incomplete therapy, and 7% completed chemotherapy. The factors associated with chemotherapy completion were nodal metastases and treatment at a National Cancer Institute-designated cancer center (p ≤ 0.05). Comorbidities decreased the odds of completion (p ≤ 0.05). The median overall survival (OS) was 14 months for the patients who received no adjuvant chemotherapy, 17 months for those who received incomplete adjuvant chemotherapy, and 22 months for those who completed adjuvant chemotherapy (p ≤ 0.05). More recent diagnosis, comorbidities, T stage, nodal metastases, and no adjuvant chemotherapy were associated with an increased hazard ratio for death (p ≤ 0.05). Evaluation of 15 or more nodes and completion of chemotherapy decreased the hazard ratio for death (p ≤ 0.05).

Conclusions

Only 7% of the Medicare patients who underwent upfront resection for pancreatic cancer completed adjuvant chemotherapy, yet completion of adjuvant chemotherapy was associated with improved OS. Completion of adjuvant chemotherapy should be the goal after upfront resection, but neoadjuvant chemotherapy may ensure that patients receive systemic chemotherapy.

Notes

Acknowledgment

The authors acknowledge Stephanie Lundgren and the entire Division of Surgical Oncology at the University of Minnesota for their assistance with this project. Ariella Altman is supported by the Institute of Basic and Applied Research in Surgery and the VFW fund of the University of Minnesota Department of Surgery. Keith Wirth is supported by NIH/NIDDK T32K108733 (MPI: Yamamoto and Beilman).

Disclosure

The authors declare that they have no conflict of interest.

Supplementary material

10434_2019_7602_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefGoogle Scholar
  2. 2.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefGoogle Scholar
  3. 3.
    Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.CrossRefGoogle Scholar
  4. 4.
    Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–75.CrossRefGoogle Scholar
  5. 5.
    Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.CrossRefGoogle Scholar
  6. 6.
    Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefGoogle Scholar
  7. 7.
    Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.CrossRefGoogle Scholar
  8. 8.
    Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Clinical Practice Guidelines: Hepatobiliary Cancers. 2018. Version 1 Retrieved 30 May 2018 at https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
  9. 9.
    Sinn M, Bahra M, Liersch T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35:3330–7.CrossRefGoogle Scholar
  10. 10.
    Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefGoogle Scholar
  11. 11.
    Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–12.CrossRefGoogle Scholar
  12. 12.
    Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.CrossRefGoogle Scholar
  13. 13.
    Labori KJ, Katz MH, Tzeng CW, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma: a population-based cohort study. Acta Oncol. 2016;55:265–77.CrossRefGoogle Scholar
  14. 14.
    Tzeng CW, Tran Cao HS, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18:16–24; discussion 24–5.Google Scholar
  15. 15.
    Aloia TA, Aloia TE, Lee JE, et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007;204:347–55.CrossRefGoogle Scholar
  16. 16.
    Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372–7.CrossRefGoogle Scholar
  17. 17.
    Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21:2873–81.CrossRefGoogle Scholar
  18. 18.
    Schwarz L, Bruno M, Parker NH, et al. Active surveillance for adverse events within 90 days: the standard for reporting surgical outcomes after pancreatectomy. Ann Surg Oncol. 2015;22:3522–9.CrossRefGoogle Scholar
  19. 19.
    SEER-Medicare Linked Database. 2018. Retrieved May 2, 2019 at https://healthcaredelivery.cancer.gov/seermedicare/.
  20. 20.
    Health NIo. About the SEER Program–SEER. National Institute of Health. 2019. Retrieved February 26, 2019 at https://seer.cancer.gov/about/overview.html.
  21. 21.
    Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.CrossRefGoogle Scholar
  22. 22.
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.CrossRefGoogle Scholar
  23. 23.
    Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Cancer. 2016;122:2979–87.CrossRefGoogle Scholar
  24. 24.
    Weinrich M, Bochow J, Kutsch AL, et al. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: a cohort study. Ann Med Surg London. 2018;32:32–7.CrossRefGoogle Scholar
  25. 25.
    Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB Oxford. 2012;14:539–47.CrossRefGoogle Scholar
  26. 26.
    Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011;34:567–72.CrossRefGoogle Scholar
  27. 27.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227–34.Google Scholar
  28. 28.
    Marmor S, Burke EE, Virnig BA, Jensen EH, Tuttle TM. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer. 2016;122:3378–85.CrossRefGoogle Scholar
  29. 29.
    Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222:638–45.CrossRefGoogle Scholar
  30. 30.
    McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007;246:246–53.CrossRefGoogle Scholar
  31. 31.
    Li HB, Zhou J, Zhao FQ. A prognostic nomogram for disease-specific survival in patients with pancreatic ductal adenocarcinoma of the head of the pancreas following pancreaticoduodenectomy. Med Sci Monit. 2018;24:6313–21.CrossRefGoogle Scholar
  32. 32.
    Valsangkar NP, Bush DM, Michaelson JS, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:257–66.CrossRefGoogle Scholar
  33. 33.
    Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–44.CrossRefGoogle Scholar
  34. 34.
    Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery.2007;141:610–18.CrossRefGoogle Scholar
  35. 35.
    Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004;70:235–40; discussion 240.Google Scholar
  36. 36.
    Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192–200.CrossRefGoogle Scholar
  37. 37.
    Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088–96.CrossRefGoogle Scholar
  38. 38.
    Heinrich S, Schäfer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014–22.CrossRefGoogle Scholar
  39. 39.
    Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3:691–7.Google Scholar
  40. 40.
    Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: a prospective cohort study involving 18,332 patients from the National Cancer Data Base. Int J Surg. 2016;34:96–102.CrossRefGoogle Scholar
  41. 41.
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):Iv-55–61.Google Scholar
  42. 42.
    Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40:201–11.CrossRefGoogle Scholar
  43. 43.
    Lamont EB, Herndon JE II, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080–3.CrossRefGoogle Scholar
  44. 44.
    Du XL, Key CR, Dickie L, Darling R, Geraci JM, Zhang D. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124–31.CrossRefGoogle Scholar
  45. 45.
    Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Med Care. 2016;54:e55–64.CrossRefGoogle Scholar
  46. 46.
    Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, version 1.2019. J Natl Compr Canc Netw. 2019;17:202–10.Google Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Ariella M. Altman
    • 1
  • Keith Wirth
    • 1
  • Schelomo Marmor
    • 1
  • Emil Lou
    • 2
  • Katherine Chang
    • 2
  • Jane Y. C. Hui
    • 1
  • Todd M. Tuttle
    • 1
  • Eric H. Jensen
    • 1
  • Jason W. Denbo
    • 1
    • 3
    Email author
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Minnesota Medical SchoolMinneapolisUSA
  2. 2.Division of Hematology, Oncology and Transplantation, Department of MedicineUniversity of Minnesota Medical SchoolMinneapolisUSA
  3. 3.Department of Gastrointestinal OncologyH. Lee Moffitt Cancer CenterTampaUSA

Personalised recommendations